Hematology Frontier

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, featuring the theme of “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event invited top hematology experts from China and abroad to discuss the latest advancements and future trends in the field.

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” As a key highlight of the conference, the Top 10 Hematology Research Advancements of 2024 were announced during the closing ceremony, recognizing significant scientific achievements in the field of hematology over the past year.

In recent years, the field of hematologic oncology has witnessed remarkable breakthroughs, with acute lymphoblastic leukemia (ALL) emerging as a focal point of progress. Chinese researchers have made significant contributions, driving milestone advancements in both research and clinical practice. To usher in the new year, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to provide an in-depth review of the key developments in ALL during 2024. This comprehensive analysis aims to guide clinical practice and inspire future research.

In recent years, the field of hematologic oncology has experienced remarkable breakthroughs, with significant advancements in mantle cell lymphoma (MCL). Chinese researchers have increasingly contributed to this progress, playing a pivotal role in driving academic development and clinical practice in the field. As we step into the new year, Hematology Frontier invited Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the major events and breakthroughs in MCL during 2024. This comprehensive summary aims to provide valuable insights for clinical practice and future research directions.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, attracting top experts, scholars, and industry leaders in the fields of cell…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together global leaders in cell and immunotherapy. This conference served as…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together leading experts, scholars, and industry leaders in the fields of…

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China. The event gathered top experts, scholars, and industry leaders in cellular and…

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the world's largest international academic conferences in the field of hematology, ASH brings together cutting-edge research and the latest drug development data, showcasing the highest level of global hematology research. During this event, Dr. Kai Hu, Director of the Lymphoma and Myeloma Department at Beijing GoBroad Boren Hospital, had multiple studies (abstracts 3079, 3387, and 1745) selected for presentation, focusing on CAR-T therapy in lymphoma and myeloma. Oncology Frontier – Hematology Frontier invited Professor Hu to share in-depth insights and analyses on these studies